Q2 2026 13F · SEC CIK 1819257
Patient Square Capital LP
Hedge fundFiled 2026-08-12 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $645.5M
- Reported positions
- 23
- Holdings vs S&P 500, 3 yrs
- —
- Assets under management
- $17.5B
Patient Square Capital LP is a hedge fund that reported 23 positions worth $645.5M in its Q2 2026 13F, filed 2026-08-12. Its largest holdings were Roivant Sciences Ltd (ROIV, 44.0%), Revolution Medicines Inc (RVMD, 8.0%), Mirum Pharmaceuticals Inc (MIRM, 4.7%).
Patient Square Capital LP holdings all 23 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| ROIVRoivant Sciences Ltd | 44.0% | -1.8% | $283.9M |
| RVMDRevolution Medicines Inc | 8.0% | — | $51.7M |
| MIRMMirum Pharmaceuticals Inc | 4.7% | +13.3% | $30.5M |
| ABVXAbivax SA | 4.3% | +70.3% | $27.5M |
| ONCBeone Medicines Ltd | 4.0% | +11.8% | $25.7M |
| PHVSPharvaris N V | 3.6% | +36.1% | $23.2M |
| ARGNFArgenx SE | 3.3% | -37.4% | $21.3M |
| UTHRUnited Therapeutics Corp Del | 3.1% | — | $20.1M |
| BLTEBelite Bio Inc | 2.6% | -5.7% | $16.9M |
| COGTCogent Biosciences Inc | 2.5% | -28.7% | $16.4M |
| DBVTDbv Technologies S A | 2.3% | +31.1% | $14.9M |
| XENEXenon Pharmaceuticals Inc | 2.1% | -3.1% | $13.3M |
| BNTXBiontech SE | 1.9% | — | $12.5M |
| RCUSArcus Biosciences Inc. | 1.7% | +82.5% | $11.0M |
| ELVNEnliven Therapeutics Inc | 1.7% | +6.3% | $10.8M |
| DNTHDianthus Therapeutics Inc | 1.6% | +15.0% | $10.5M |
| ALLOAllogene Therapeutics Inc | 1.6% | +46.4% | $10.5M |
| EYPTEyepoint Pharmaceuticals Inc | 1.6% | -9.4% | $10.3M |
| ARQTArcutis Biotherapeutics Inc | 1.5% | -7.6% | $9.7M |
| CCCCC4 Therapeutics Inc | 1.2% | — | $7.5M |
| IVAInventiva SA | 1.2% | — | $7.4M |
| KYMRKymera Therapeutics Inc | 0.8% | -52.5% | $5.4M |
| FTHFaeth Therapeutics Inc | 0.7% | — | $4.4M |
What Patient Square Capital LP bought and sold in Q2 2026, against Q1 2026.
New positions
- RVMD Revolution Medicines Inc8.0% of 13F
- UTHR United Therapeutics Corp Del3.1% of 13F
- BNTX Biontech SE1.9% of 13F
- CCCC C4 Therapeutics Inc1.2% of 13F
- IVA Inventiva SA1.2% of 13F
- FTH Faeth Therapeutics Inc0.7% of 13F
Added to
- RCUS Arcus Biosciences Inc.+82.5% shares
- ABVX Abivax SA+70.3% shares
- ALLO Allogene Therapeutics Inc+46.4% shares
- PHVS Pharvaris N V+36.1% shares
- DBVT Dbv Technologies S A+31.1% shares
- DNTH Dianthus Therapeutics Inc+15.0% shares
- MIRM Mirum Pharmaceuticals Inc+13.3% shares
- ONC Beone Medicines Ltd+11.8% shares
Reduced
- KYMR Kymera Therapeutics Inc-52.5% shares
- ARGNF Argenx SE-37.4% shares
- COGT Cogent Biosciences Inc-28.7% shares
- EYPT Eyepoint Pharmaceuticals Inc-9.4% shares
- ARQT Arcutis Biotherapeutics Inc-7.6% shares
- BLTE Belite Bio Inc-5.7% shares
Sold out
- INSM Insmed Incwas 4.6%
- LEGN Legend Biotech Corpwas 3.2%
- NKTR Nektar Therapeuticswas 2.7%
- CELC Celcuity Incwas 1.9%
- MRK Merck & Co Incwas 1.7%
- CATX Perspective Therapeutics Incwas 1.2%
- Definium Therapeutics Incwas 1.1%
- HROW Harrow Incwas 1.0%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +106.9% /yr
- S&P 500 +20.1%
- 3 years
- —
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $645.5M | 23 |
| Q1 2026 | $563.6M | 29 |
| Q4 2025 | $467.1M | 28 |
| Q3 2025 | $373.9M | 24 |
| Q2 2025 | $277.4M | 19 |
| Q1 2025 | $241.7M | 19 |
| Q4 2024 | $267.4M | 20 |
| Q3 2024 | $269.4M | 11 |
Questions about Patient Square Capital LP's portfolio
What stocks does Patient Square Capital LP own?
Patient Square Capital LP's latest 13F, for Q2 2026 and filed Aug 12, 2026, lists 23 positions worth $645.5M. The largest are Roivant Sciences Ltd (ROIV) at 44.0%, Revolution Medicines Inc (RVMD) at 8.0%, Mirum Pharmaceuticals Inc (MIRM) at 4.7%, Abivax SA (ABVX) at 4.3% and Beone Medicines Ltd (ONC) at 4.0%.
What did Patient Square Capital LP buy last quarter?
In Q2 2026, Patient Square Capital LP added a new position in Revolution Medicines Inc (RVMD), a new position in United Therapeutics Corp Del (UTHR), a new position in Biontech SE (BNTX), a new position in C4 Therapeutics Inc (CCCC), a new position in Inventiva SA (IVA), Arcus Biosciences Inc. (RCUS) (+82.5% shares), Abivax SA (ABVX) (+70.3% shares) and Allogene Therapeutics Inc (ALLO) (+46.4% shares), compared with its Q1 2026 filing.
What did Patient Square Capital LP sell last quarter?
In Q2 2026, Patient Square Capital LP sold all of Insmed Inc (INSM), sold all of Legend Biotech Corp (LEGN), sold all of Nektar Therapeutics (NKTR), sold all of Celcuity Inc (CELC), sold all of Merck & Co Inc (MRK), Kymera Therapeutics Inc (KYMR) (-52.5% shares), Argenx SE (ARGNF) (-37.4% shares) and Cogent Biosciences Inc (COGT) (-28.7% shares), compared with its Q1 2026 filing.
When is Patient Square Capital LP's next 13F filing due?
13F filings are due 45 days after each quarter ends. Patient Square Capital LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Patient Square Capital LP manage?
Patient Square Capital LP reported $17.5B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $645.5M.